SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
Open Access
- 1 July 2021
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Cardiology Reviews
- Vol. 16 (4) , 258-265
Abstract
A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.Keywords
This publication has 29 references indexed in Scilit:
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trialsDiabetes & Vascular Disease Research, 2015
- Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on MetforminDiabetes Care, 2015
- Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 DiabetesDiabetes Care, 2014
- Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)Cardiovascular Diabetology, 2014
- Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trialAmerican Heart Journal, 2013
- The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)Journal of Diabetes and its Complications, 2013
- The Role of the Kidney and Sodium-Glucose Cotransporter-2 Inhibition in Diabetes ManagementClinical Diabetes, 2012
- Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 DiabetesDiabetes Care, 2012
- Effects of SGLT2 inhibitors on cardiovascular outcomesDiabetes & Vascular Disease Research, 2012
- SGLT2 inhibition — a novel strategy for diabetes treatmentNature Reviews Drug Discovery, 2010